A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPD

COPD is one of the leading causes of disability and in the top five causes of death worldwide. Early diagnosis and treatment are essential to slow the decline of lung function and improve quality of life.

The current standard for diagnosing COPD is spirometry; an effort-dependent test that requires supervised use, by a specifically trained medical professional, in a clinic-based environment. It is estimated that up to 2/3 of cases are undiagnosed suggesting that there is a significant care gap in the ability to accurately diagnose COPD.

Asthma is a chronic respiratory disease, characterised by airway inflammation and hyper-responsiveness. In 2019 affected an estimated 262 million people. Early diagnosis and treatment are important to reduce symptoms, exacerbations and mortality and to improve overall quality of life. The confirmation of reversible airflow obstruction using pre- and post-bronchodilator (BD) spirometry is needed to confirm a diagnosis in those suspected as having asthma without evidence of inflammation in the airways or blood.

Spirometry can be challenging for patients to perform, is time consuming and can be challenging to deliver at the scale required by the population.

TidalSense have been developing respiratory diagnostic devices that could offer simpler, safe, fast, reliable and precise tests to diagnose both COPD and asthma.

It is anticipated that successfully meeting the primary objectives of this study will result in data on the diagnostic accuracy of the COPD diagnostic models and could lead to the development and improvement of all diagnostic algorithms used in the study. This may contribute to a range of future clinical benefits:

• Accurate diagnosis of asthma and/or COPD
• Accurate detection of severe COPD in patients who are likely or highly likely to have COPD
• Improved ease of testing for asthma and/or COPD for patients and healthcare professionals
• Clearer differentiation between asthma and COPD in patients with overlapping symptoms

These benefits could enable quicker testing, improve patient experience (relaxed breathing instead of forced breathing), and improve patient access to testing compared to current diagnostic pathways and reduce misdiagnosis.

Inclusion criteria

• Age ≥ 18 years
• Referred for respiratory diagnostic testing with a clinical suspicion of asthma or COPD
• Participant is willing and able to provide informed consent

Exclusion criteria

• Referred for respiratory diagnostic testing for a condition other than asthma or COPD, with no mention in the referral of a clinical suspicion of COPD or asthma
• Participants who, in the opinion of the chief investigator, or their delegate, are unlikely to comply with the requirements of the study
• Inability to give written informed consent
• Participants who are acutely unwell
• Patients unable to breathe through their mouths e.g. tracheostomy patients